Table 2 Antibacterial and antifungal therapy for children with probable/proven invasive pulmonary aspergillosis

Antibacterial therapy on the diagnosis of IPA

0.511

 Meropenem with teicoplanin

15 (50.0)

10 (66.7)

 Meropenem

7 (23.3)

2 (13.3)

 Piperacillin/tazobactam with isepamicin

4 (13.3)

3 (20.0)

 Cefepime

1 (3.3)

0 (0.0)

 None

3 (10.0)

0 (0.0)

Anti-fungal prophylaxis

0.327

 No prophylaxis

11 (36.7)

3 (20.0)

 Oral fluconazole

15 (50.0)

11 (73.3)

 Oral itraconazole or intravenous micafungin

4 (13.3)

1 (6.7)

First-line antifungal agents

 Amphotericin B deoxycholate

28 (93.3)

9 (60.0)

0.059

 Liposomal amphotericin B

1 (3.3)

2 (13.3)

 Caspofungin

0 (0.0)

1 (6.7)

 Itraconazole

1 (3.3)

1 (6.7)

 Intravenous voriconazole

0 (0.0)

2 (13.3)

Final antifungal agents

0.657

 Amphotericin B deoxycholate

1 (3.3)

1 (6.7)

 Liposomal amphotericin B

2 (6.7)

1 (6.7)

 Caspofungin

3 (10.0)

1 (6.7)

 Itraconazole (oral)

0 (0.0)

1 (6.7)

 Voriconazole (intravenous or oral)

24 (80.0)

11 (73.3)

Total duration of fever (days)

7 (1–32)

17 (1–64)

0.031

Duration of neutropenia after antifungal therapy

0.006

 ≤2 weeks

21 (70.0)

4 (26.7)

 >2 weeks

9 (30.0)

11 (73.3)